Join Xeris Biopharma for an in-person and virtual analyst and investor day in New York featuring three key opinion leaders (KOLs), who will join company management to discuss evolving market dynamics, unmet medical needs, and the near- and long-term outlook for Recorlev^®, and its late-stage candidate, XP-8121, a Phase 3-ready, once-weekly, subcutaneous injection for treating hypothyroidism.

This event will offer an opportunity to share deeper insights into the Company’s strategic vision and future initiatives.

There will be a live Q&A session following the formal presentations. Virtual participants will also have the opportunity to submit questions live.